Through a partnership with IBM, Moderna is exploring the use of quantum computing and generative AI technology in the development of future mRNA drugs.
Biotechnology company Moderna and IBM have announced an agreement under which Moderna will explore next-generation technologies such as quantum computing and artificial intelligence to advance and accelerate mRNA research and science.
"Since our inception, we have always strived to be at the forefront of cutting-edge technology and use innovation to make the greatest impact on people through mRNA medicines," said Stéphane Bancel, CEO of Moderna. “We are excited to work with IBM to develop new AI models to advance mRNA science, prepare for the quantum computing era, and prepare our business for these disruptive technologies. We are pursuing breakthrough advances in quantum computing, so we are investing now in building a quantum-ready workforce so that we are fully prepared to harness the power of this technology.”
Developing quantum computing skills for mRNA medicine design
Quantum computing is a rapidly developing and transformative technology that uses the principles of quantum mechanics to solve problems too complex for classical computers. Modern scientists will learn how quantum technology could be applied to previously intractable problems for classical computers.
Together, the companies will explore the potential application of quantum approaches to Moderna's scientific challenges.
Moderna will join the IBM Quantum Accelerator program and the IBM Quantum Network. Under the agreement, IBM will provide access to quantum computing systems as well as expertise to help Moderna explore cutting-edge life sciences use cases powered by quantum technologies.
AI models for mRNA medicine design
Moderna and IBM scientists will use MoLFormer, a basic artificial intelligence model that can help scientists predict the properties of a molecule and could help them understand the characteristics of potential mRNA drugs. Using MoLFormer, Moderna's goal will be to help optimize lipid nanoparticles that encapsulate and protect mRNA as it moves through the body, and mRNA that acts as instructions for cells to fight disease. In this initiative, Moderna and IBM will combine state-of-the-art formulation discovery with generative AI to design mRNA drugs with optimal safety and performance.
“IBM's purpose is to be a catalyst to make the world work better, which is perfectly illustrated by this partnership with Moderna. We are witnessing a revolution in the world of computing, driven by extraordinary advances in artificial intelligence and quantum computing," said Dr Darío Gil, senior vice president and director of research at IBM.
“Moderna will be able to leverage our multi-year research efforts in generative artificial intelligence for therapeutics that will allow scientists to better understand how molecules behave and can facilitate the creation of entirely new ones. We are also excited to work with Moderna to help equip their scientists with the knowledge and use of IBM's cutting-edge quantum computing technologies to accelerate the discovery and development of new therapeutics.”
Post a Comment
you have any problem , please let me know.